Valneva’s Chikungunya Vaccine Shows Antibody Persistence
Valneva’s investigational chikungunya vaccine candidate VLA1553 showed positive results in an antibody persistence trial. Chikungunya is a viral disease transmitted by an infected mosquito.
The clinical trial, which followed a phase 3 study, tracked 363 participants from month 6 after vaccination to month 12, showed 99 percent of participants maintaining an acceptable level of neutralizing antibody titers. The ongoing study will monitor a subset of participants for at least five years.
Valneva expects to complete its submission of a Biologics License Application by the end of this year.